Health Matters for Women - July 2022

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

July 2022 

You Are Invited: Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners Webinar

The HHS Office of Minority Health and CDC’s Office of Minority Health and Health Equity invite you to attend the Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners Webinar on Friday, July 29, from 1:30 p.m. to 3:00 p.m. (ET). The webinar will provide accurate, timely, and trusted information about how to protect all children from COVID-19. Speakers include pediatric vaccine experts from HHS, CDC, and community partners leading vaccine efforts for children and youth.

New from CDC Authors

Condom Use among Women of Reproductive Age (18-49 years) in Puerto Rico During the 2016 Zika Virus (ZIKV) Outbreak: Secondary Analysis of Data from a Cross-sectional, Population-based, Cell-phone Survey

Contraception is a medical countermeasure to reduce unintended pregnancy and ZIKV-associated birth defects. We estimated the prevalence of condom use and associated factors among women at risk for unintended pregnancy in Puerto Rico during the 2016 ZIKV outbreak.

Genital Microbiota of Women Using a 90 Day Tenofovir or Tenofovir and Levonorgestrel Intravaginal Ring in a Placebo Controlled Randomized Safety Trial in Kenya

Intravaginal rings (IVRs) are a safe, discreet and effective option for simultaneous delivery of contraception and antiretrovirals. In a phase-IIa trial, study authors investigated the influence of 90 days continuous-delivery tenofovir (TFV) IVRs with/without levonorgestrel (LNG) on the genital microbiota of Kenyan women. Microbiota shifts could influence genital health and ability of the female genital tract to protect against infections including sexually transmitted infections.

Human Papillomavirus Vaccine Beliefs and Practice Characteristics in Rural and Urban Adolescent Care Providers

The human papillomavirus (HPV) vaccine is recommended for all adolescents age 11-12 years. HPV vaccine coverage remains suboptimal in the United States though, particularly in rural areas. This study surveyed adolescent immunization providers in two Midwestern states to assess rural vs. urban differences in HPV vaccine resources, practices, and attitudes.

A Risk Measurement Tool for Targeted HIV Prevention Measures amongst Young Pregnant and Lactating Women in South Africa

The progress made towards reducing AIDS-related deaths has not been matched with equal progress in reducing new HIV infections. Young women ages 15-24 years continue to account for a disproportionate number of new infections. This study aimed to develop and validate a tool to identify which pregnant/lactating young South African women (≤ 24 years) are at risk of HIV infection.

Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available

In the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines, clinical management decisions are based on immediate and 5-year cervical intraepithelial neoplasia (CIN) 3+ risk estimates. However, data for technologies other than human papillomavirus testing and cytology may be limited to clinical trials and observational studies of shorter duration than 5 years. In this study, to enable decisions about 1- or 3-year intervals, 3-year CIN 3+ risk equivalents to 5-year CIN 3+ risk thresholds were generated.

Progress Towards the UNAIDS 95-95-95 Targets among Pregnant Women in South Africa: Results from the 2017 and 2019 National Antenatal HIV Sentinel Surveys

The UNAIDS 95-95-95 global targets for epidemic control aim to ensure by 2030 that 95% of HIV-positive people know their HIV status, 95% of people diagnosed with HIV receive sustained antiretroviral therapy (ART), and 95% of people on ART have viral suppression. This study assessed progress towards the 95-95-95 targets among pregnant women between the ages of 15-49 years attending public health facilities in South Africa.

New from CDC Authors: COVID-19 Impact on Women

Gestational SARS-CoV-2 Infection is Associated with Placental _expression_ of Immune and Trophoblast Genes

Maternal SARS-CoV-2 infection during pregnancy is associated with adverse pregnancy outcomes and can have effects on the placenta, even in the absence of severe disease or vertical transmission to the fetus. This study aimed to evaluate histopathologic and molecular effects in the placenta after SARS-CoV-2 infection during pregnancy.

Perinatal COVID-19 Maternal and Neonatal Outcomes at Two Academic Birth Hospitals

In utero fetal infection from pregnant mothers with SARS-CoV-2 infection appears rare. Maternal/newborn transmission during and immediately after delivery seems to occur with greater frequency, and risk may be decreased with infection prevention practices. This study sought to describe the relationship between perinatal COVID-19 and maternal and newborn health outcomes, and our local incidence of newborn SARS-CoV-2 infection during the delivery admission and within 1 month after birth, over a 13-month period at two urban, high-risk birth hospitals.

National, State, Territorial and Local
Select Announcements, Statements, Reports, and Events from National, State, Territorial, and Local Agencies and Organizations

11th Annual Conference: Breast Cancer and African Americans (BCAA) - Stanford Cancer Institute's Office of Cancer Health Equity and Community Engagement

Health Observances, August 2022

National Breastfeeding Month

8/1 – 8/7 World Breastfeeding Week
National Immunization Awareness Month

If you're having trouble reading this message, click here

This service is provided by the CDC/ATSDR Office of Women's Health. Email comments or suggestions to owh@xxxxxxx.

For more information about women’s health, visit


The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Links to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC/ATSDR or the Federal Government, and none should be inferred. The CDC/ATSDR is not responsible for the content of the individual organization Web pages found at these links.

Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  | 

[Index of Archives]     [NIH News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [SB Lupus]     [STB]
  Powered by Linux